Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 4/20 | 0.42 |
| ▸ | PRKAA2 | P54646 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 6/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | GPR6 | P46095 | 1/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5465709 | 0.89 | PRKAA2 (0.50) | EGFRPRKAA2MEN1KMT2A | |
| SCHEMBL5330700 | 0.87 | EGFR (0.45) | EGFRPRKAA2ABCG2MEN1KMT2A | |
| SCHEMBL5462750 | 0.86 | EGFR (0.43) | EGFRPRKAA2ABCG2MEN1KMT2A | |
| SCHEMBL5463988 | 0.85 | EGFR (0.43) | EGFRPRKAA2ABCG2MKNK2TP53 | |
| SCHEMBL5462901 | 0.85 | DCLK1 (0.48) | EGFRABCG2MKNK2TP53 | |
| SCHEMBL5463510 | 0.84 | PRKAA2 (0.47) | EGFRPRKAA2MEN1 | |
| SCHEMBL5463882 | 0.84 | EGFR (0.54) | EGFR | |
| SCHEMBL5462805 | 0.83 | PRKAA2 (0.42) | EGFRPRKAA2ABCG2MEN1KMT2A | |
| SCHEMBL5463029 | 0.81 | SOS1 (0.46) | EGFRMEN1KMT2A | |
| SCHEMBL5469705 | 0.81 | HTR2B (0.49) | EGFRPRKAA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070244133-A1 | Thienopyrimidines and Thiazolopyrimidines for Use in Medicine | ASTRAZENECA AB (SE) | 2007-10-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244133-A1 | Thienopyrimidines and Thiazolopyrimidines for Use in Medicine | CXCR4, CXCR1, CXCR3 | EGFR 4385/4885PRKAA2 4108/4885ALDH1A1 683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.